Search
Vinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIt is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … ICA-105665 is a novel small molecule compound for the treatment of epilepsy.
Aptazapine
go.drugbank.com/drugs/DB09305ExperimentalAlthough Aptazapine reached clinical trials, it was never marketed. … Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity.
Altrenogest
go.drugbank.com/drugs/DB11372ExperimentalVet approvedAltrenogest, also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals.
OPB-111077
go.drugbank.com/drugs/DB16630InvestigationalOPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
Emprumapimod
go.drugbank.com/drugs/DB17603InvestigationalEmprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
HMI-103
go.drugbank.com/drugs/DB17684InvestigationalHMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Col-Treg
go.drugbank.com/drugs/DB18451ExperimentalCol-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]
Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagenHRS-1167
go.drugbank.com/drugs/DB18703InvestigationalHRS-1167 is under investigation in clinical trial NCT05473624 (Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors).
RCT1100
go.drugbank.com/drugs/DB18830InvestigationalRCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]